<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654028</url>
  </required_header>
  <id_info>
    <org_study_id>AT/HCC</org_study_id>
    <nct_id>NCT02654028</nct_id>
  </id_info>
  <brief_title>Association Between Autologous Transfusion and Recurrence Among Patients With HCC After Resection</brief_title>
  <acronym>AT/HCC</acronym>
  <official_title>Association Between Autologous Transfusion and Tumor Recurrence Among Patients With Hepatocellular Carcinoma After Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aims to determine whether autotransfusion of red blood cells salvaged
      during liver resection is associated with the recurrence of hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative and intraoperative blood salvage autotransfusion is used in various surgical
      procedures. However, because of the risk of reinfusion of salvaged blood contaminated by
      tumor cells, the use of autotransfusion in hepatocellular carcinoma (HCC) patients undergoing
      liver resection is controversial. The critical points include whether tumor cells can be
      cleared by autotransfusion, whether autotransfusion increases the risk of recurrence or
      metastasis, and what are the indications for autotransfusion. Moreover, some other issues are
      still not addressed. For example, is it warranted to take the risk of tumor dissemination by
      using autotransfusion to avoid allogeneic blood transfusion? Do the remaining tumor cells
      after additional filtration by leukocyte depletion filters still possess potential
      tumorigenicity?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with tumor recurrence</measure>
    <time_frame>1-year</time_frame>
    <description>The 1-year tumor recurrence will be compared between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Autotransfusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These group of patients will receive autotransfusion before liver resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These group of patients will not receive autotransfusion before or after liver resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autotransfusion</intervention_name>
    <description>These group of patients will receive autotransfusion before liver resection.</description>
    <arm_group_label>Autotransfusion group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>These group of patients will not receive autotransfusion before or after liver resection.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who underwent open liver resection.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian-Hong Zhong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Le-Qun Li, MD</last_name>
    <phone>86-0771-5330855</phone>
    <email>xitongpingjia@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian-Hong Zhong, MD</last_name>
    <email>zhongjianhong66@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>5350032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Le-Qun Li, MD</last_name>
      <email>xitongpingjia@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Han S, Kim G, Ko JS, Sinn DH, Yang JD, Joh JW, Lee SK, Gwak MS. Safety of the Use of Blood Salvage and Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma. Ann Surg. 2016 Aug;264(2):339-43. doi: 10.1097/SLA.0000000000001486.</citation>
    <PMID>26501715</PMID>
  </results_reference>
  <results_reference>
    <citation>Tomimaru Y, Eguchi H, Wada H, Hama N, Kawamoto K, Kobayashi S, Umeshita K, Doki Y, Mori M, Nagano H. Predicting the necessity of autologous blood collection and storage before surgery for hepatocellular carcinoma. J Surg Oncol. 2013 Dec;108(7):486-91. doi: 10.1002/jso.23426. Epub 2013 Sep 5.</citation>
    <PMID>24009154</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

